Kelebihan berat badan menjadi faktor risiko penyakit tidak menular demikian juga dengan lingkar perut. Kedua indikator tersebut banyak dijumpai pada usia produktif termasuk mahasiswa. Pola hidup sehat merupakan kunci untuk mencegah kelebihan berat badan dan lingkar perut. Penelitian ini bertujuan untuk menganilisis pengaruh program edukasi hidup sehat dalam menurunkan berat badan dan lingkat perut. Metode Penelitian yang digunakan adalah quasi experiment without control. Variabel dependen adalah berat badan dan lingkar perut dan variabel independen adalah program hidup sehat. Populasi sasaran adalah seluruh mahasiswa program studi D3 Keperawatan yang berjumlah 93 orang. Teknik pengambilan sampel menggunakan purposive sampling. Kriteria Inklusi adalah mahasiswa atau mahasiswi yang memiliki berat badan lebih dari normal. Sementara kriteria ekslusif adalah mahasiswa yang memiliki riwayat hipertensi atau diabetes mellitus serta mahasiswa yang dalam kondisi sakit saat dilakukan skrening. Data calon responden diperoleh dari skriningpopulasi sasaran dan diseleksi berdasarkan kriteria inklusi. Jumlah sampel sebanyak 28 orang. Di awal pertemuan responden diberikan edukasi selama 60 menit dan diberikan lembaran program hidup sehat yang dijalankan dan dilaporkan setiap hari selama 7 hari. Setelah dilakukan pretest dan post, kedua data diolah dan dilakukan uji normalitas data dan hasilnya > 0,05 yang berarti data distribusi normal. Hasil. Hasil uji t berpasangan, berat badan sebelum dan sesudah program edukasi didapatkan p-value 0,000 sementara lingkar perut sebelum dan sesudah program edukasi didapatkan p-value 0,000. Program pola hidup sehat yang dijalankan secara konsisten terutama dalam pembatasan jumlah makanan tinggi karbohidrat dan lemak serta melakukan aktifitas fisik dapat mengurangi pembentukan lemak tubuh. Kesimpulan. Program edukasi hidup sehat hidup sehat yang dijalankan selama 7 hari memiliki pengaruh terhadap penurunan berat badan dan lingkar perut.
{"title":"Pengaruh Program Edukası Hıdup Sehat terhadap Penurunan Berat Badan dan Lıngkar Perut pada Mahasıswa Keperawatan","authors":"Haris Haris","doi":"10.57174/j.born.v3i2.99","DOIUrl":"https://doi.org/10.57174/j.born.v3i2.99","url":null,"abstract":"Kelebihan berat badan menjadi faktor risiko penyakit tidak menular demikian juga dengan lingkar perut. Kedua indikator tersebut banyak dijumpai pada usia produktif termasuk mahasiswa. Pola hidup sehat merupakan kunci untuk mencegah kelebihan berat badan dan lingkar perut. Penelitian ini bertujuan untuk menganilisis pengaruh program edukasi hidup sehat dalam menurunkan berat badan dan lingkat perut. Metode Penelitian yang digunakan adalah quasi experiment without control. Variabel dependen adalah berat badan dan lingkar perut dan variabel independen adalah program hidup sehat. Populasi sasaran adalah seluruh mahasiswa program studi D3 Keperawatan yang berjumlah 93 orang. Teknik pengambilan sampel menggunakan purposive sampling. Kriteria Inklusi adalah mahasiswa atau mahasiswi yang memiliki berat badan lebih dari normal. Sementara kriteria ekslusif adalah mahasiswa yang memiliki riwayat hipertensi atau diabetes mellitus serta mahasiswa yang dalam kondisi sakit saat dilakukan skrening. Data calon responden diperoleh dari skriningpopulasi sasaran dan diseleksi berdasarkan kriteria inklusi. Jumlah sampel sebanyak 28 orang. Di awal pertemuan responden diberikan edukasi selama 60 menit dan diberikan lembaran program hidup sehat yang dijalankan dan dilaporkan setiap hari selama 7 hari. Setelah dilakukan pretest dan post, kedua data diolah dan dilakukan uji normalitas data dan hasilnya > 0,05 yang berarti data distribusi normal. Hasil. Hasil uji t berpasangan, berat badan sebelum dan sesudah program edukasi didapatkan p-value 0,000 sementara lingkar perut sebelum dan sesudah program edukasi didapatkan p-value 0,000. Program pola hidup sehat yang dijalankan secara konsisten terutama dalam pembatasan jumlah makanan tinggi karbohidrat dan lemak serta melakukan aktifitas fisik dapat mengurangi pembentukan lemak tubuh. Kesimpulan. Program edukasi hidup sehat hidup sehat yang dijalankan selama 7 hari memiliki pengaruh terhadap penurunan berat badan dan lingkar perut.","PeriodicalId":9118,"journal":{"name":"Borneo Journal of Pharmacy","volume":"79 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76793313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Emmanuel Israel Edache, Adamu Uzairu, Paul Andrew Mamza, Gideon Adamu Shallangwa
Graves' disease (GD) is an autoimmune condition that frequently causes hyperthyroidism and thyrotoxicosis. Protein tyrosine phosphatase, non-receptor type 22 (lymphoid) isoform 1 (PTPN22), is a promising therapeutic candidate for treating GD, rheumatoid arthritis, type 1 diabetes, and other autoimmune disorders. In this dataset, 31 molecular compounds and two standard drugs were optimized using the semi-empirical PM7 theory method via MOPAC v22.0.4 to reveal the key influencing factors contributing to their grave's disease inhibition activity and selectivity. Using QSARIN software, the acquired properties/descriptors were used to create a quantitative structural activities relationship (QSAR) model, and the similarities between the observed and predicted pIC50 values were examined. A molecular docking simulation study also uncovers non-covalent interactions between the investigated compounds and the receptors. The observed ligand-protein interactions with GD proteins (PDB ID 2XPG and 4QT5) and PTPN22 (PDB ID 3BRH) were investigated. The pharmacokinetics (ADMET) properties were also investigated. Finally, molecular dynamics (MD) simulation and MM/GBSA studies that demonstrated stable trajectory and molecular properties with a consistent interaction profile were used to validate the stability of the compounds in the complex with PTPN22.
格雷夫斯病(GD)是一种自身免疫性疾病，经常引起甲状腺功能亢进和甲状腺毒症。蛋白酪氨酸磷酸酶，非受体22型(淋巴样)异构体1 (PTPN22)，是治疗GD，类风湿性关节炎，1型糖尿病和其他自身免疫性疾病的有希望的治疗候选者。在MOPAC v22.0.4平台上，采用半经验PM7理论方法对31个分子化合物和2个标准药物进行优化，揭示影响其抑癌活性和选择性的关键因素。利用QSARIN软件，利用获得的属性/描述符创建定量结构活性关系(QSAR)模型，并检验观测值与预测值之间的相似性。分子对接模拟研究也揭示了所研究的化合物与受体之间的非共价相互作用。观察到的配体蛋白与GD蛋白(PDB ID 2XPG和4QT5)和PTPN22 (PDB ID 3BRH)的相互作用。并研究了其药代动力学(ADMET)特性。最后，通过分子动力学(MD)模拟和MM/GBSA研究，验证了PTPN22配合物的稳定性。结果表明，PTPN22具有稳定的相互作用轨迹和分子特性。
{"title":"2D-QSAR, Docking, Molecular Dynamics Simulations with the MM/GBSA Approaches against Graves' Disease and PTPN22","authors":"Emmanuel Israel Edache, Adamu Uzairu, Paul Andrew Mamza, Gideon Adamu Shallangwa","doi":"10.33084/bjop.v6i3.4915","DOIUrl":"https://doi.org/10.33084/bjop.v6i3.4915","url":null,"abstract":"Graves' disease (GD) is an autoimmune condition that frequently causes hyperthyroidism and thyrotoxicosis. Protein tyrosine phosphatase, non-receptor type 22 (lymphoid) isoform 1 (PTPN22), is a promising therapeutic candidate for treating GD, rheumatoid arthritis, type 1 diabetes, and other autoimmune disorders. In this dataset, 31 molecular compounds and two standard drugs were optimized using the semi-empirical PM7 theory method via MOPAC v22.0.4 to reveal the key influencing factors contributing to their grave's disease inhibition activity and selectivity. Using QSARIN software, the acquired properties/descriptors were used to create a quantitative structural activities relationship (QSAR) model, and the similarities between the observed and predicted pIC50 values were examined. A molecular docking simulation study also uncovers non-covalent interactions between the investigated compounds and the receptors. The observed ligand-protein interactions with GD proteins (PDB ID 2XPG and 4QT5) and PTPN22 (PDB ID 3BRH) were investigated. The pharmacokinetics (ADMET) properties were also investigated. Finally, molecular dynamics (MD) simulation and MM/GBSA studies that demonstrated stable trajectory and molecular properties with a consistent interaction profile were used to validate the stability of the compounds in the complex with PTPN22.","PeriodicalId":9118,"journal":{"name":"Borneo Journal of Pharmacy","volume":"101 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136242061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Wirda Anggraini, Fitria Rahma Fauzia, Arief Suryadinata, Burhan Ma'arif, Ni Nyoman Sri Budayanti, Fransiska Rosari Dewi
Coronavirus disease-19 (Covid-19) is a pandemic that has caused various complications, including pneumonia. One of the therapies used in Covid-19 with pneumonia complications is antibiotics. Antibiotics must be used appropriately to prevent antibiotic resistance. A method to reduce the number of antibiotic resistances is evaluating the use of antibiotics qualitatively using the Gyssens method. Therefore, this study aims to describe the profile and rationality of using pneumonia antibiotics for adult Covid-19 patients at X Hospital from January to December 2020. The data was collected retrospectively on adult patients using the patient's medical record data, and the sample was determined using the purposive sampling technique. There were 117 samples of medical record data processed in this study. This study concluded that the use of antibiotics for patients with Covid-19 disease consisted of single antibiotic usage, i.e., azithromycin in 82 cases (70.09%), and levofloxacin in 30 cases (25.64%), and switched antibiotics usage, i.e., azithromycin to levofloxacin in 5 cases (4.27%). The rationality of using antibiotics using the Gyssens methods was 90.60% with rational or appropriate antibiotics use (category 0). Moreover, there was 9.40% irrational drug use (category I-VI), comprising antibiotics for a longer time than it should be, in 11 cases.
{"title":"Qualitative Evaluation on the Use of Pneumonia Antibiotics for Covid-19 Patients at X Hospital Bali in 2020","authors":"Wirda Anggraini, Fitria Rahma Fauzia, Arief Suryadinata, Burhan Ma'arif, Ni Nyoman Sri Budayanti, Fransiska Rosari Dewi","doi":"10.33084/bjop.v6i3.2855","DOIUrl":"https://doi.org/10.33084/bjop.v6i3.2855","url":null,"abstract":"Coronavirus disease-19 (Covid-19) is a pandemic that has caused various complications, including pneumonia. One of the therapies used in Covid-19 with pneumonia complications is antibiotics. Antibiotics must be used appropriately to prevent antibiotic resistance. A method to reduce the number of antibiotic resistances is evaluating the use of antibiotics qualitatively using the Gyssens method. Therefore, this study aims to describe the profile and rationality of using pneumonia antibiotics for adult Covid-19 patients at X Hospital from January to December 2020. The data was collected retrospectively on adult patients using the patient's medical record data, and the sample was determined using the purposive sampling technique. There were 117 samples of medical record data processed in this study. This study concluded that the use of antibiotics for patients with Covid-19 disease consisted of single antibiotic usage, i.e., azithromycin in 82 cases (70.09%), and levofloxacin in 30 cases (25.64%), and switched antibiotics usage, i.e., azithromycin to levofloxacin in 5 cases (4.27%). The rationality of using antibiotics using the Gyssens methods was 90.60% with rational or appropriate antibiotics use (category 0). Moreover, there was 9.40% irrational drug use (category I-VI), comprising antibiotics for a longer time than it should be, in 11 cases.","PeriodicalId":9118,"journal":{"name":"Borneo Journal of Pharmacy","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136242059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
This study aimed to evaluate the antidiabetic potential of compounds from Anogeissus leiocarpus in silico and the potential of the compounds as antidiabetic drug candidates. Molecular docking (MD), molecular dynamics simulation (MDS), and ADMET were carried out in silico to evaluate the compounds' antidiabetic potential and drug candidacy. The MDS revealed the least BA (-8.7 kcal/mol) was exhibited by compound X (palmitic acid) with Glucagon-like Peptide-1 Receptor (GLP1), while the highest BA (-5.8 kcal/mol) was demonstrated by I (1,2,4-benzetriol) with dipeptidyl peptidase IV (DPP-4) among the best interactions. The MDS result showed good docked complexes' flexibility, deformability, and stability with low eigenvalues ranging from 8.52 × 10-5 to 1.30 × 10-4. All the compounds had a bioavailability score of 0.55 except VI (0.85), while the synthetic ability showed a good score of ≤3.01. Eight compounds were predicted to be soluble, with two poorly soluble. Additionally, all the compounds had high gastrointestinal absorption, with the majority being blood-brain barrier permeant, while skin permeation value was between -2.55 and -7.48 cm/s. Furthermore, none of the compounds were either permeability glycoprotein (P-gp) substrate or CYP2C19 and CYP2C9 inhibitors, though some were CYP1A2, CYP2D6, and CYP3A4 inhibitors. Moreover, the toxicity study showed moderate to non-toxicity results with toxicity classes between 3 and 5. Conclusively, the compounds from A. leiocarpus showed good binding interactions, which are the protein targets of antidiabetic therapy and potentially good candidates for antidiabetic drug development.
{"title":"Potential Antidiabetic Compounds from Anogeissus leiocarpus: Molecular Docking, Molecular Dynamic Simulation, and ADMET Studies","authors":"Mubarak Muhammad Dahiru, Neksumi Musa, AbdulAzeez Mumsiri Abaka, Maimuna Abdulrahman Abubakar","doi":"10.33084/bjop.v6i3.5027","DOIUrl":"https://doi.org/10.33084/bjop.v6i3.5027","url":null,"abstract":"This study aimed to evaluate the antidiabetic potential of compounds from Anogeissus leiocarpus in silico and the potential of the compounds as antidiabetic drug candidates. Molecular docking (MD), molecular dynamics simulation (MDS), and ADMET were carried out in silico to evaluate the compounds' antidiabetic potential and drug candidacy. The MDS revealed the least BA (-8.7 kcal/mol) was exhibited by compound X (palmitic acid) with Glucagon-like Peptide-1 Receptor (GLP1), while the highest BA (-5.8 kcal/mol) was demonstrated by I (1,2,4-benzetriol) with dipeptidyl peptidase IV (DPP-4) among the best interactions. The MDS result showed good docked complexes' flexibility, deformability, and stability with low eigenvalues ranging from 8.52 × 10-5 to 1.30 × 10-4. All the compounds had a bioavailability score of 0.55 except VI (0.85), while the synthetic ability showed a good score of ≤3.01. Eight compounds were predicted to be soluble, with two poorly soluble. Additionally, all the compounds had high gastrointestinal absorption, with the majority being blood-brain barrier permeant, while skin permeation value was between -2.55 and -7.48 cm/s. Furthermore, none of the compounds were either permeability glycoprotein (P-gp) substrate or CYP2C19 and CYP2C9 inhibitors, though some were CYP1A2, CYP2D6, and CYP3A4 inhibitors. Moreover, the toxicity study showed moderate to non-toxicity results with toxicity classes between 3 and 5. Conclusively, the compounds from A. leiocarpus showed good binding interactions, which are the protein targets of antidiabetic therapy and potentially good candidates for antidiabetic drug development.","PeriodicalId":9118,"journal":{"name":"Borneo Journal of Pharmacy","volume":"2018 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136242057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Agustina Nila Yuliawati, Pande Made Desy Ratnasari, Ni Luh Putu Satria Maharani
End-stage renal disease (ESRD) patients undergoing hemodialysis (HD) repeatedly can affect their quality of life (QOL). Its QOL value can vary according to the patient's characteristics amid health conditions that may make it difficult for them. This study aimed to analyze the QOL of ESRD patients undergoing HD and its affecting factors. This cross-sectional study was conducted in a Hemodialysis Outpatient Unit of General Hospital, Denpasar, Bali, from April to May 2021. A sample of 103 respondents was obtained by using the purposive sampling technique. Inclusion criteria were ESRD patients undergoing HD aged ≥8 years old, completing questionnaires thoroughly, and communicating well. Data was collected through the KDQOL-36 questionnaire to measure the QOL and medical records for completeness of patient identities. Data were analyzed using Spearman's ρ, η, Mann-Whitney, and an Independent sample t-test (CI 95%). Findings showed the majority of respondents were aged <60 years (75.7%), had secondary education (41.7%), were working (50.5%), were diagnosed with ESRD, and undergoing HD <3 Years (81.6%), the duration of each HD >4 hours (85.4%), three times a week (91.3%), having a BMI >29 kg/m2 (89.3%), and hypertension (42.7%). The respondents experienced major problems in their QOL on the burden of ESRD (33.50±24.64), physical (39.57±8.94), and mental component summary (52.62±10.39) dimensions. Respondent's characteristics, including education level, duration of each HD, and diagnosis with ESRD undergoing HD, contributed to their QOL (p <0.05). The patient's QOL needs to be improved through the family and health worker's support.
{"title":"Quality of Life in End-Stage Renal Disease Patients Undergoing Hemodialysis and Its Affecting Factors in a Hemodialysis Unit of General Hospital Denpasar","authors":"Agustina Nila Yuliawati, Pande Made Desy Ratnasari, Ni Luh Putu Satria Maharani","doi":"10.33084/bjop.v6i3.3907","DOIUrl":"https://doi.org/10.33084/bjop.v6i3.3907","url":null,"abstract":"End-stage renal disease (ESRD) patients undergoing hemodialysis (HD) repeatedly can affect their quality of life (QOL). Its QOL value can vary according to the patient's characteristics amid health conditions that may make it difficult for them. This study aimed to analyze the QOL of ESRD patients undergoing HD and its affecting factors. This cross-sectional study was conducted in a Hemodialysis Outpatient Unit of General Hospital, Denpasar, Bali, from April to May 2021. A sample of 103 respondents was obtained by using the purposive sampling technique. Inclusion criteria were ESRD patients undergoing HD aged ≥8 years old, completing questionnaires thoroughly, and communicating well. Data was collected through the KDQOL-36 questionnaire to measure the QOL and medical records for completeness of patient identities. Data were analyzed using Spearman's ρ, η, Mann-Whitney, and an Independent sample t-test (CI 95%). Findings showed the majority of respondents were aged <60 years (75.7%), had secondary education (41.7%), were working (50.5%), were diagnosed with ESRD, and undergoing HD <3 Years (81.6%), the duration of each HD >4 hours (85.4%), three times a week (91.3%), having a BMI >29 kg/m2 (89.3%), and hypertension (42.7%). The respondents experienced major problems in their QOL on the burden of ESRD (33.50±24.64), physical (39.57±8.94), and mental component summary (52.62±10.39) dimensions. Respondent's characteristics, including education level, duration of each HD, and diagnosis with ESRD undergoing HD, contributed to their QOL (p <0.05). The patient's QOL needs to be improved through the family and health worker's support.","PeriodicalId":9118,"journal":{"name":"Borneo Journal of Pharmacy","volume":"22 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136242058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rebhika Lusiana, Achmad Toto Poernomo, Achmad Syahrani
In the entire world, cardiovascular diseases (CVDs) are the main cause of death. For the treatment of CVDs, microbial fibrinolytic enzymes are highly regarded as novel therapeutic candidates. This study was purposed to determine the fibrinolytic protease activity produced by fungus source, which is Rhizopus microsporus var. oligosporus FNCC 6010 in fermented sunflower (Helianthus annuus) seed and common bean (Phaseolus vulgaris) seed. Fermentation was carried out by solid-state fermentation method at an initial pH of 5, incubation temperature of 33±1°C, and incubation time of 24 hours. The fermented seed was extracted to obtain supernatant as the crude enzyme. The proteolytic activity assay was done by the skimmed milk agar (SMA) plate method to obtain the proteolytic index, and the fibrinolytic activity assay was conducted by the fibrin-agarose plate method to get the fibrinolytic index. The results show that crude enzymes from fermented H. annuus and P. vulgaris seeds by R. microsporus have fibrinolytic protease activity with proteolytic index 2.64 ± 0.01 and 2.23 ± 0.04, respectively. The fibrinolytic index is 2.40 ± 0.06 and 1.64 ± 0.06, respectively. Therefore, the crude enzyme has the potential to be further researched as a candidate for thrombolytic agents. The purification, characterization, and in-depth research are needed to develop enzymes into preparations for preventing and treating CVDs.
在全世界，心血管疾病(cvd)是导致死亡的主要原因。对于心血管疾病的治疗，微生物纤溶酶被高度认为是一种新的治疗候选者。本研究旨在测定真菌源小孢子根霉(Rhizopus microsporus var. oligosporus) FNCC 6010对向日葵(Helianthus annuus)种子和菜豆(Phaseolus vulgaris)种子发酵后产生的纤溶蛋白酶活性。采用固态发酵法发酵，初始pH为5，培养温度为33±1℃，培养时间为24小时。提取发酵后的种子得到上清液作为粗酶。蛋白水解活性测定采用脱脂乳琼脂(SMA)平板法获得蛋白水解指数，纤溶活性测定采用纤维蛋白-琼脂糖平板法获得纤溶指数。结果表明，小孢子镰刀菌发酵的黄芪和黄芪种子粗酶具有纤溶酶活性，蛋白酶水解指数分别为2.64±0.01和2.23±0.04。纤溶指数分别为2.40±0.06和1.64±0.06。因此，粗酶作为一种候选溶栓剂具有进一步研究的潜力。酶的纯化、表征和深入研究是开发预防和治疗心血管疾病制剂的必要条件。
{"title":"Fibrinolytic Protease Activity of Crude Enzyme from Fermented Sunflower (Helianthus annuus) and Common Bean (Phaseolus vulgaris) seeds by Rhizopus microsporus var. oligosporus FNCC 6010 in Solid State Fermentation","authors":"Rebhika Lusiana, Achmad Toto Poernomo, Achmad Syahrani","doi":"10.33084/bjop.v6i3.4665","DOIUrl":"https://doi.org/10.33084/bjop.v6i3.4665","url":null,"abstract":"In the entire world, cardiovascular diseases (CVDs) are the main cause of death. For the treatment of CVDs, microbial fibrinolytic enzymes are highly regarded as novel therapeutic candidates. This study was purposed to determine the fibrinolytic protease activity produced by fungus source, which is Rhizopus microsporus var. oligosporus FNCC 6010 in fermented sunflower (Helianthus annuus) seed and common bean (Phaseolus vulgaris) seed. Fermentation was carried out by solid-state fermentation method at an initial pH of 5, incubation temperature of 33±1°C, and incubation time of 24 hours. The fermented seed was extracted to obtain supernatant as the crude enzyme. The proteolytic activity assay was done by the skimmed milk agar (SMA) plate method to obtain the proteolytic index, and the fibrinolytic activity assay was conducted by the fibrin-agarose plate method to get the fibrinolytic index. The results show that crude enzymes from fermented H. annuus and P. vulgaris seeds by R. microsporus have fibrinolytic protease activity with proteolytic index 2.64 ± 0.01 and 2.23 ± 0.04, respectively. The fibrinolytic index is 2.40 ± 0.06 and 1.64 ± 0.06, respectively. Therefore, the crude enzyme has the potential to be further researched as a candidate for thrombolytic agents. The purification, characterization, and in-depth research are needed to develop enzymes into preparations for preventing and treating CVDs.","PeriodicalId":9118,"journal":{"name":"Borneo Journal of Pharmacy","volume":"21 1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136242063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Although few studies are reported, Hua gabonii remains scientifically unknown due to the lack of studies. However, this aromatic plant is used in developing countries as a condiment or in traditional medicine to treat various ailments. The literature reported that this species is rich in proteins, essential amino acids, and vitamins C and E. Its fruits would present an appreciable antioxidant power. Therefore, given its numerous uses in tropical countries, H. gabonii is a good candidate for further studies.
{"title":"Utilization, Phytochemistry and Biological Activity of Hua gabonii Pierre ex De Wild.","authors":"Clément Mutunda Mbadiko, Gédéon Ngiala Bongo, Jean-Paul Koto-te-Nyiwa Ngbolua, Marie Claire Dembo D’A Letshu Yandju, Pius Tshimankinda Mpiana, Théophile Fundu Mbemba","doi":"10.33084/bjop.v6i3.4239","DOIUrl":"https://doi.org/10.33084/bjop.v6i3.4239","url":null,"abstract":"Although few studies are reported, Hua gabonii remains scientifically unknown due to the lack of studies. However, this aromatic plant is used in developing countries as a condiment or in traditional medicine to treat various ailments. The literature reported that this species is rich in proteins, essential amino acids, and vitamins C and E. Its fruits would present an appreciable antioxidant power. Therefore, given its numerous uses in tropical countries, H. gabonii is a good candidate for further studies.","PeriodicalId":9118,"journal":{"name":"Borneo Journal of Pharmacy","volume":"22 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136242066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nathan Isaac Dibal, Zainab Muhammad Goni, Martha Orendu Oche Attah, Umar Imam, Muhammad Abdullahi, Muzammil Bashir, Usman Adam, Fatima Aisami, Mohammed Shuwa, Sunday Joseph Manye, Madu Nom Gadzama, Musa Samaila Chiroma, Helga Bedan Ishaya
High-fat diet alone or in combination with high fructose has been known to induce diabetes, obesity, hypertension, and immune dysfunction. The study evaluates the role of Aloe vera in fat-rich and high fructose diet-induced (FRHFD) hyperglycemias in addition to testicular and splenic morphology in mice. Twenty BALB/c Mice were randomly distributed into four groups (n=5). The groups were fed on a normal diet, FRHFD, FRHFD + 10 g A. vera, and FRHFD + 20 g A. vera for 10 weeks. All the mice were sacrificed a day after the 10 weeks of treatment. The result showed that mice fed on FRHFD plus A. vera had a significantly lower (p<0.05) blood glucose level relative to the FRHFD-fed mice. The mice fed on FRHFD plus A. vera had a significantly lower (p<0.05) blood glucose level relative to the FRHFD-fed mice. Aloe vera was found to ameliorate FRHFD-induced pancreatic islet and acini damage. It also prevented distorted lymphoid cells and testicular damage induced by FRHFD. Aloe vera prevents hyperglycemia and protects pancreatic islets in FRHFD-fed mice. It further prevents immune dysfunction and protects against testicular damage. Hence, A. vera supplementation could be an alternative and/or complementary therapy for hyperglycemia-related disorders.
已知高脂肪饮食单独或与高果糖结合可诱发糖尿病、肥胖、高血压和免疫功能障碍。该研究评估了芦荟在高脂肪和高果糖饮食诱导(FRHFD)高血糖症中的作用，以及小鼠睾丸和脾脏形态。20只BALB/c小鼠随机分为4组(n=5)。各组分别饲喂正常饲粮、FRHFD、FRHFD + 10 g a . vera和FRHFD + 20 g a . vera，为期10周。所有小鼠在治疗10周后的第一天被处死。结果表明，与FRHFD组相比，FRHFD组小鼠的血糖水平显著降低(p < 0.05)。与FRHFD组相比，FRHFD + a . vera组的血糖水平显著降低(p < 0.05)。发现芦荟可改善frhfd诱导的胰岛和腺泡损伤。它还能防止FRHFD引起的淋巴样细胞畸变和睾丸损伤。芦荟可预防小鼠高血糖和保护胰岛。它进一步防止免疫功能障碍和防止睾丸损伤。因此，芦荟补充剂可能是高血糖相关疾病的替代和/或补充治疗。
{"title":"Aloe vera Gel Ameliorates Fat-Rich and High Fructose (FRHF) Diet-Induced Pancreatic and Splenic Damage in Mice","authors":"Nathan Isaac Dibal, Zainab Muhammad Goni, Martha Orendu Oche Attah, Umar Imam, Muhammad Abdullahi, Muzammil Bashir, Usman Adam, Fatima Aisami, Mohammed Shuwa, Sunday Joseph Manye, Madu Nom Gadzama, Musa Samaila Chiroma, Helga Bedan Ishaya","doi":"10.33084/bjop.v6i3.5351","DOIUrl":"https://doi.org/10.33084/bjop.v6i3.5351","url":null,"abstract":"High-fat diet alone or in combination with high fructose has been known to induce diabetes, obesity, hypertension, and immune dysfunction. The study evaluates the role of Aloe vera in fat-rich and high fructose diet-induced (FRHFD) hyperglycemias in addition to testicular and splenic morphology in mice. Twenty BALB/c Mice were randomly distributed into four groups (n=5). The groups were fed on a normal diet, FRHFD, FRHFD + 10 g A. vera, and FRHFD + 20 g A. vera for 10 weeks. All the mice were sacrificed a day after the 10 weeks of treatment. The result showed that mice fed on FRHFD plus A. vera had a significantly lower (p<0.05) blood glucose level relative to the FRHFD-fed mice. The mice fed on FRHFD plus A. vera had a significantly lower (p<0.05) blood glucose level relative to the FRHFD-fed mice. Aloe vera was found to ameliorate FRHFD-induced pancreatic islet and acini damage. It also prevented distorted lymphoid cells and testicular damage induced by FRHFD. Aloe vera prevents hyperglycemia and protects pancreatic islets in FRHFD-fed mice. It further prevents immune dysfunction and protects against testicular damage. Hence, A. vera supplementation could be an alternative and/or complementary therapy for hyperglycemia-related disorders.","PeriodicalId":9118,"journal":{"name":"Borneo Journal of Pharmacy","volume":"9 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136242072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The leaves of the temurui (Murraya koenigii (Linn.) Spreng) plant have long been known and used by Indonesian and even Asian people as a traditional medicine to treat stomach aches and diabetes. This study aimed to determine the secondary metabolite profile of the methanol extract of M. koenigii leaves. Murraya koenigii leaves fine powder was extracted in stages using n-hexane, ethyl acetate, and methanol. Each extract was prepared using a mixture of water, formic acid, acetonitrile, and formic acid, then injected into the UPLC-MS, then analyzed with MassLynx and ChemSpider. The results showed that the metabolite profile of the methanol extract of M. koenigii leaves contained 13 compounds, including phenolic, steroid, and alkaloid groups. Those compounds could be tested to identify their bioactivity.
{"title":"Characterization of Secondary Metabolites Profile from Methanol Fraction of Temurui (Murraya koenigii (Linn.) Spreng) Leaves Using UPLC-MS","authors":"Intania Permata, Adlis Santoni, Afrizal Afrizal, Trisno Afandi","doi":"10.33084/bjop.v6i3.4662","DOIUrl":"https://doi.org/10.33084/bjop.v6i3.4662","url":null,"abstract":"The leaves of the temurui (Murraya koenigii (Linn.) Spreng) plant have long been known and used by Indonesian and even Asian people as a traditional medicine to treat stomach aches and diabetes. This study aimed to determine the secondary metabolite profile of the methanol extract of M. koenigii leaves. Murraya koenigii leaves fine powder was extracted in stages using n-hexane, ethyl acetate, and methanol. Each extract was prepared using a mixture of water, formic acid, acetonitrile, and formic acid, then injected into the UPLC-MS, then analyzed with MassLynx and ChemSpider. The results showed that the metabolite profile of the methanol extract of M. koenigii leaves contained 13 compounds, including phenolic, steroid, and alkaloid groups. Those compounds could be tested to identify their bioactivity.","PeriodicalId":9118,"journal":{"name":"Borneo Journal of Pharmacy","volume":"11 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136242064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Assalamu’alaikum Wr. Wb.
Alhamdulillahirabbil ‘alamin. The next edition of Borneo Journal of Pharmacy (Borneo J Pharm), has been published at August 2023. This edition contains ten articles: Pharmacology-Toxicology, Analytical Pharmacy-Medicinal Chemistry, Natural Product Development, Microbiology Pharmacy, and Clinical-Community Pharmacy. This edition includes writings from five countries: Cyprus, Indonesia, Malaysia, Nigeria, and the Democratic Republic of the Congo. The authors come from several institutions, including University of Maiduguri, Cyprus International University, Newcastle University Medicine Malaysia, Ahmadu Bello University, Adamawa State Polytechnic, Modibbo Adama University, Politeknik ATI Padang, Universitas Andalas, Politeknik Teknologi Kimia Industri Medan, Université de Kinshasa, Universitas Airlangga, Universitas Ahmad Dahlan, Universitas Islam Negeri Maulana Malik Ibrahim, Universitas Udayana, Institut Teknologi dan Kesehatan Bali, Sekolah Tinggi Farmasi Mahaganesha, and Universitas Gadjah Mada.
Editorial boards are fully aware that there are still room for improvement in this edition, hence with all humility willing to accept constructive suggestions and feedback for improvements to the publication for the next editions. The editorial board would like to thank all editors and reviewers, and contributors of the scientific articles who have provided the repetoire in this issue. We hope that all parties, especially the contributors, could re-participate for the publication in the next edition on November 2023.
Wassalamu’alaikum Wr. Wb.
{"title":"Cover, Content, and Editorial Note from Borneo J Pharm Vol. 6 No. 3 August 2023","authors":"Chief Editor of Borneo J Pharm","doi":"10.33084/bjop.v6i3.6067","DOIUrl":"https://doi.org/10.33084/bjop.v6i3.6067","url":null,"abstract":"Assalamu’alaikum Wr. Wb.
 Alhamdulillahirabbil ‘alamin. The next edition of Borneo Journal of Pharmacy (Borneo J Pharm), has been published at August 2023. This edition contains ten articles: Pharmacology-Toxicology, Analytical Pharmacy-Medicinal Chemistry, Natural Product Development, Microbiology Pharmacy, and Clinical-Community Pharmacy. This edition includes writings from five countries: Cyprus, Indonesia, Malaysia, Nigeria, and the Democratic Republic of the Congo. The authors come from several institutions, including University of Maiduguri, Cyprus International University, Newcastle University Medicine Malaysia, Ahmadu Bello University, Adamawa State Polytechnic, Modibbo Adama University, Politeknik ATI Padang, Universitas Andalas, Politeknik Teknologi Kimia Industri Medan, Université de Kinshasa, Universitas Airlangga, Universitas Ahmad Dahlan, Universitas Islam Negeri Maulana Malik Ibrahim, Universitas Udayana, Institut Teknologi dan Kesehatan Bali, Sekolah Tinggi Farmasi Mahaganesha, and Universitas Gadjah Mada.
 Editorial boards are fully aware that there are still room for improvement in this edition, hence with all humility willing to accept constructive suggestions and feedback for improvements to the publication for the next editions. The editorial board would like to thank all editors and reviewers, and contributors of the scientific articles who have provided the repetoire in this issue. We hope that all parties, especially the contributors, could re-participate for the publication in the next edition on November 2023.
 Wassalamu’alaikum Wr. Wb.","PeriodicalId":9118,"journal":{"name":"Borneo Journal of Pharmacy","volume":"116 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136242060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：